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ABSTRACT
Data collected since the discovery of p53 and pRb/RB1 suggests these tumor 
suppressors cooperate to inhibit tumor progression. Patients who have mutations in 
both p53 and RB1 genes have increased tumor reoccurrence and decreased survival 
compared to patients with only one tumor suppressor gene inactivated. It remains 
unclear how p53 and pRb cooperate toward inhibiting tumorigenesis. Using RNA 
expression profiling we identified 179 p53 and pRb cross-talk candidates in normal 
lung fibroblasts (WI38) cells exogenously coexpressing p53 and pRb. Regulator of G 
protein signaling 16 (RGS16) was among the p53 and pRb cross-talk candidates and 
has been implicated in inhibiting activation of several oncogenic pathways associated 
with proliferation, migration, and invasion of cancer cells.
RGS16 has been found to be downregulated in pancreatic cancer patients with 
metastases compared to patients without metastasis. Expression of RGS16 mRNA was 
decreased in the pancreatic cancer cell lines tested compared to control. Expression 
of RGS16 inhibited migration of the BxPC-3 and AsPC-1 but not PANC-1 cells and 
inhibited invasion of BxPC-3 and AsPC-1 cells with no impact on cell viability. We have 
identified for the first time p53 and pRb cross-talk candidates and a role for RGS16 
to inhibit pancreatic cancer migration and invasion.
INTRODUCTION
The p53 and pRb tumor suppressors are two 
signaling pathways that are frequently altered during 
cancer progression. Mutations that disrupt the p53 and 
pRb pathways can occur in the gene sequences or in their 
upstream regulators and/or downstream effectors. Results 
of studies have found that both tumor suppressor genes 
are inactivated in a variety of malignancies including 
osteosarcoma, small cell lung, breast, and bladder 
carcinomas [1-4]. Furthermore, alterations in expression 
or activity of proteins involved in p53 and pRb signaling 
pathways have been identified in retinoblastoma and 
cancers of the pancreas, colon, and head and neck among 
others [5-8]. The large number of cancers that have defects 
in the p53 and pRb pathways demonstrates the importance 
of these genes in preventing cancer development and 
progression.
Existing data suggests that p53 and pRb cooperate to 
prevent tumor progression. Examples of this cooperative 
interaction have been shown by various studies using 
human primary cancer samples and mouse models. 
Patients who have mutations in both p53 and RB1 genes 
have increased tumor recurrence and decreased survival 
compared to patients with a mutation in either p53 or 
RB1 [1, 9, 10]. A study conducted in mice found that 
p53 null mice who were also heterozygous for RB1 were 
susceptible to developing more tumors than mice with 
single mutations; i.e. heterozygous p53 or RB1 null or 
p53 null mice [4]. In another study, mice with conditional 
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inactivation of both p53 and RB1 in prostate epithelium 
developed highly metastatic tumors and had decreased 
survival time compared to mice with single p53 or RB1 
inactivation [11]. The accumulated evidence suggests p53 
and RB1 gene products have cooperative or synergistic 
effects for cancer suppression.
Considering the network of communication that 
exists within a cell, the rate of mutation of p53 and RB1, 
and the cellular processes these two proteins regulate, a 
natural hypothesis is that these two genes and respective 
gene products cross-communicate in order to determine 
cellular fate and prevent carcinogenesis. In fact, there 
are known examples of genes and proteins that are 
involved in the convergent signaling between the p53 
and pRb pathways; such as Hdm2, p21, E2F-1 and the 
INK4a locus (reviewed in [9, 12-14]). Although several 
proteins that are involved in the p53 and pRb pathways 
have been identified, the full extent in which these two 
tumor suppressors interact along their pathway to regulate 
cellular fate is still unknown. To identify downstream 
targets of both p53 and pRb regulation and to elucidate 
mechanisms of p53 and pRb cross-talk, we coexpressed 
p53 and pRb in normal human lung fibroblast cells 
(WI38) and used RNA expression profiling to identify 
up- or down-regulated genes. We identified Regulator of 
G protein Signaling 16 (RGS16) as a p53 and pRb cross-
talk candidate.
RGS16, previously found to be induced by 
doxorubicin in cells expressing wild-type p53, belongs 
to a large family of proteins that plays a role in swiftly 
shutting down G protein-coupled receptor (GPCR) 
signaling pathways [15, 16]. RGS16 is a GTPase 
activating protein (GAP) that aids GTPase activity of 
the α-subunit of G proteins associated with G-protein 
coupled receptors (GPCR). RGS16 has been implicated in 
negatively regulating the MAPK, AKT/PI3K, RhoA, and 
SDF-1/CXCR4 oncogene pathways in normal or cancer 
cell lines [15, 17-19]. These oncogene pathways have 
been implicated in cancer progression processes (such 
as proliferation, survival, chemoresistance, migration, 
invasion, and metastasis in a variety of malignancies 
including pancreatic cancer [20-24]. Recently, evidence 
has demonstrated a role of RGS16 in cancer signaling. 
RGS16 locus is a site of genomic instability in (50% of 
222) primary breast tumors and knockdown of RGS16 
in breast cancer cell lines increases Epidermal Growth 
Factor (EGF) and Fetal Bovine Serum (FBS) initiated 
proliferation [19, 25]. A previous report using tissue 
microarray analysis revealed decreased expression of 
Regulator of G-protein signaling 16 (RGS16) in pancreatic 
tumors with lymph-node metastases compared to non-
metastasized pancreatic cancer and this loss was associated 
with decreased patient survival [26]. Based upon the link 
of RGS16 regulating several oncogenic pathways and the 
decreased expression of RGS16 in metastasized pancreatic 
cancer, we chose to further study the function of RGS16 in 
pancreatic cancer in order to identify the role it has in the 
p53 and pRb signaling pathways. Currently, RGS16 has 
not been linked with inhibition of cancer cell metastasis 
nor has its function been investigated to understand it’s 
downregulation in metastasized pancreatic cancer. The 
majority of patients newly diagnosed with pancreatic 
cancer present with highly progressed and/or metastatic 
cancer that is resistant to treatment [27, 28]. Due to the late 
stage of diagnosis and the aggressive nature of this disease, 
less than 20% of pancreatic cancer patients are eligible for 
the potentially curative surgery [28, 29]. Therefore, there 
is a great need for more effective drugs aimed at treating or 
preventing metastatic pancreatic cancer. Pancreatic cancer 
is associated with p53 mutations and p16 (pRb activator) 
deletions resulting in the crippling of both the p53 and pRb 
pathways. By investigating the p53 and pRb cross-talk and 
the role of RGS16 in pancreatic cancer cell migration, we 
have uncovered a novel regulator of metastasis processes 
that could be a future target in developing treatments for 
metastatic pancreatic cancer.
RESULTS
Identification of p53 and pRb cross-talk 
candidates in WI38 cells following coexpression 
of p53 and/or pRb
Studies have shown that p53 and pRb cooperate 
to prevent tumorigenesis. Currently, the molecules 
that function in the p53 and pRb cross-talk pathway to 
regulate cellular fate are not known thus expression 
profiling by microarray was performed to find genes co-
regulated by p53 and pRb. Normal human lung WI38 
fibroblast cells were transduced with adenoviral vectors 
expressing the p53 and/or RB1 genes under the control of 
a cytomegalovirus (CMV) promoter. The WI38 cell line 
was used because it is from non-cancerous tissue and lacks 
mutations or viral transformations that could disrupt the 
p53 and pRb pathways. Four experimental conditions were 
used in which WI38 cells were transduced with adenovirus 
vector control (cond. 1, Adenoviral CMV-vector control, 
Ad.CMV.p53 (cond. 2), Ad.CMV.pRb (cond. 3), or both 
Ad.CMV.p53 and Ad.CMV.pRb (cond. 4). RNA and 
protein from WI38 cells was collected 48 hours after 
adenoviral infection. Immunoblots verified increased 
expression of p53 (fold change compared to Ad.CMV 
control = 2.80, 1.54, and 2.77) and/or hypophosphorylated 
(active form) pRb (hypophosphorylated/total pRb fold 
change compared to Ad.CMV control = 0.94, 5.48, 5.02) in 
the WI38 cells treated with adenoviruses containing p53, 
pRb, or both p53 and pRb respectively (Figure 1A and 
1B). Fold change values for p53 and hypophosphorylated 
pRb coincided with previously reported results in 
experiments that activated endogenous p53 and pRb 
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[30, 31]. Microarray data from the adenovirus vector 
control (empty vector with CMV promoter) was used as 
a reference to determine genes that were differentially 
expressed as a consequence of p53, pRb, and p53 + pRb 
expression. Analysis of the microarray data identified 294-
p53, 650-pRb, and 514-p53 + pRb differentially expressed 
genes (Figure 1C; see Supplementary Document 1 for full 
list of differentially expressed genes). Of the differentially 
expressed genes, 294/294 genes were upregulated in cells 
with p53 expression, 427/650 genes were upregulated in 
cells with pRb expression, and 319/514 genes were up-
regulated in cells with p53 + pRb coexpression (Figure 
1C). Consistent with protein measurements, increased 
expression of p53 and/or RB1 mRNAs were also found 
in the appropriate groups (Supplementary Document 1).
A Venn diagram shows the number of differentially 
expressed genes shared between the experimental groups 
(Figure 1C). By looking at the common genes between 
the three experimental groups, we were able to generate 
two lists of genes that may be involved in the p53 and pRb 
cross-talk pathway. The first list of cross-talk candidates 
(designated as the p53 and pRb common gene set) 
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consisted of 39 genes found to be commonly up-regulated 
in cells expressing either p53 or pRb. The second list of 
possible cross-talk members (designated as the p53 and 
pRb interaction gene set) contained 140 genes that were 
found to be differentially expressed only when p53 and 
pRb were overexpressed together (see Supplementary 
Document 1). Thirty-two of the 39 common gene set 
cross-talk candidates were found to be up-regulated 
in the interaction gene set, while the remaining 7 were 
commonly up-regulated in cells that overexpress either 
p53 or pRb (Table 1). By focusing on the common and 
interaction gene sets, we were able to remove transcripts 
that were up- or down-regulated by only p53 or pRb and 
focus on candidates that may be involved in the p53 and 
pRb cross-talk pathway.
qRT-PCR validation of microarray data in WI38 
and SAOS-2 cells
Our ultimate goal in performing the microarray 
analysis was to determine molecules involved in the p53 
and pRb cross-talk pathway in order to identify and study 
downstream effector molecules that can be expressed 
to induce a p53 and/or pRb tumor suppressive function. 
Because of our interest in identifying downstream effector 
molecules, we chose five mRNA transcripts (IL-6, BTG-2, 
STAT4, RGS16, BCL2L11) from the set of 39 commonly 
up- regulated transcripts by p53 and pRb for validation via 
qRT-PCR. IL-6, BTG-2, STAT4, RGS16, and BCL2L11 
were chosen for validation because of varying function, 
known regulation by p53 and pRb, and fold change values 
expression profiling assay. WI38 cells were plated and 
transduced with adenoviral expression vectors via the 
same methods used for the microarray analysis. Relative 
fold change was calculated for IL-6, BTG-2, STAT4, 
RGS16, and BCL2L11 in WI38 cells expressing p53 and/
or pRb as shown in Figure 2. Statistically significant up- 
regulation of all transcripts tested except BCL2L11 was 
found in WI38 cells expressing p53 and pRb confirming 
the microarray results. Expression of p53 and pRb in 
WI38 cells increased mRNA expression for some of the 
transcripts (for example, RGS16 and BTG-2) to a greater 
extent than single expression of either p53 or pRb. This 
suggests p53 and pRb are working together resulting in an 
additive (i.e. BTG-2) or synergistic (i.e. RGS16) effect on 
mRNA expression for some of the transcripts.
To further support the RNA expression profiling 
results, we repeated the expression of p53 and pRb in 
a p53 null, RB1 mutant osteosarcoma cell line (SAOS-
2) and performed qRT- PCR analysis of IL-6, BTG-2, 
Figure 1: Identification of differentially expressed 
transcripts in WI38 cells expressing p53 and/or pRb. 
WI38 cells were transduced with adenoviruses carrying the 
transgenes p53, or RB1/p105; a MOI of 50 was used in each 
case. A) Western blot analysis was used to test for p53 and 
pRb expression prior to microarray analysis. B) Fold change 
of protein expressions compared to CMV control. C) A Venn 
diagram shows the differentially expressed transcripts and 
intersects identified during the microarray analysis. The numbers 
in red denote transcripts that were up-regulated due to p53, pRb, 
or p53 and pRb expression.
Figure 2: Validation of microarray data using qRT-
PCR in WI38 cells. Five transcripts RGS16, BCL2L11, 
BTG2, IL-6 and STAT4 from the p53 and pRb intersect were 
chosen for validation by qRT-PCR in WI38 cells expressing p53, 
pRb, or both p53 and pRb. The vector control (Ad.CMV) was 
used to calculate the fold change for each transcript. One-way 
ANOVA with Dunnett’s test for multiple comparison were used 
to test for statistical significance * p-value < 0.05, ** p-value < 
0.01, *** p-value < 0.001, and **** p-value < 0.0001.
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STAT4, RGS16, and BCL2L11. The expression of all five 
transcripts including IL-6 and BCL2L11 were found to be 
significantly increased by one-way ANOVA compared to 
vector control in SAOS-2 cells expressing p53 and/or pRb 
(Figure 3). Dunnett’s test for multiple comparison found 
BCL2L11 expression to be significantly increased in cells 
expressing p53, pRb, and both p53 and pRb and IL-6 was 
found to be significantly increased in cells expressing 
pRb and p53+pRb. Expression of IL-6 was not found to 
be statistically significant in SAOS-2 cells expressing p53 
due to variation between replicates (fold change= 2.86). 
All five transcripts were found to be up-regulated when 
p53 and/or pRb were expressed in the microarray analysis 
and qRT-PCR analysis showed similar results in WI38 and 
SAOS-2 cells.
mRNA expression of RGS16 is decreased in 
pancreatic cancer cell lines
RGS16 was identified as a p53 and pRb cross-
talk candidate in our expression profiling analysis that 
was validated by qRT-PCR. We chose to study the role 
of RGS16 in pancreatic cancer cell migration due in 
part to its down-regulation in patients with metastasized 
pancreatic cancer and the high rate of p53 mutations 
(50-70%) and p16 deletions (85%) affecting both the 
p53 and pRb pathways in this disease [6, 7, 26]. We first 
investigated the relative expression of RGS16 mRNA in 
four pancreatic cancer cell lines (BxPC-3, MIA PaCa-
2, PANC-1, and AsPC-1) in order to characterize the 
endogenous expression of RGS16. Expression of RGS16 
Figure 3: Validation of microarray data using qRT-
PCR in SAOS-2 cells. Five transcripts RGS16, BCL2L11, 
BTG2, IL-6 and STAT4 from the p53 and pRb intersect were 
chosen for validation by qRT-PCR in SAOS-2 cells expressing 
p53, pRb, or both p53 and pRb. The vector control (Ad.CMV) 
was used to calculate the fold change for each transcript. One-
way ANOVA with Dunnett’s test for multiple comparison were 
used to test for statistical significance * p-value < 0.05, ** 
p-value < 0.01, *** p-value < 0.001, and **** p-value < 0.0001.
Figure 4: Decreased expression of RGS16 mRNA 
relative to total RNA extracted from normal human 
pancreatic tissue. Expression of RGS16 was measured using 
qRT-PCR in BxPC-3, MIA PaCa-2, PANC-1, and AsPC-1 cells. 
Relative fold change was measured using total RNA extracted 
from normal human pancreatic tissue as the control. One-way 
ANOVA with Tukey’s test for multiple comparison were used to 
test for statistical significance between the cell lines and control 
* p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001, and 
**** p-value <0.0001.
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was measured by qRT-PCR analysis and the relative 
RGS16 mRNA fold change was calculated in the four 
cell lines compared to total RNA from normal human 
pancreatic tissue. Expression of RGS16 was decreased 
in all four lines compared to control with BxPC-3 having 
the highest expression of RGS16 mRNA (Figure 4). 
Expression of RGS16 varied between the four lines with 
BxPC-3 and MIA PaCa-2 having significantly higher 
expression of RGS16 than PANC-1 and the metastatic 
derived AsPC-1 cells. RGS16 expression corresponded 
with the more differentiated and less aggressive cell lines 
having higher levels of RGS16 than the more aggressive 
and/or metastatic cell lines (Table 2).
RGS16 inhibited migration of BxPC-3 and AsPC-
1 pancreatic cancer cells but not PANC-1
To test the hypothesis that RGS16 inhibits 
pancreatic cancer cell migration, we exogenously 
expressed RGS16 in BxPC-3, PANC-1, and AsPC-1 
cells with an adenoviral vector and used wound healing 
assays to measure cell migration. We chose BxPC-3, 
PANC-1, and AsPC-1 because these three cell lines are 
Figure 5: Expression of RGS16 inhibited migration of BxPC-3 cells. BxPC-3 cells were transduced with 50 MOI of Ad.GFP 
(CTRL) or Ad.GFP.RGS16.  A) Virus transduction was verified by fluorescent microscopy. B) Images (100x) and measurements of wounds 
were taken prior and 16 hours after addition of media supplemented with FBS (10%) or EGF (100ng/ml). The dashed lines represent size 
of scratch at time 0.  C) Mean Percentage of wound healing ± SEM of three separate experiments (three scratches / well) was determined. 
Student’s t-test was used to determine statistical significance compared to control * p-value < 0.05, ** p-value <0.01.
Figure 6: Expression of RGS16 did not inhibit migration of PANC-1 cells. Wound healing assays were performed as described 
in Figure 2. A) Fluorescent microscopy was used to verify virus transductions: B) 100 X images were taken of migrating cells and C) 
percentages of wound healing were calculated at 24hrs following addition of FBS or EGF.
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derived from tumors with varying expression of RGS16, 
differentiation status, mutations, presence of metastases, 
and expression of Epidermal Growth Factor Receptor 
(EGRF, Table 2). We expressed RGS16 using adenoviral 
vector that contains RGS16 plus a GFP reporter (Ad.GFP.
RGS16) and used a vector expressing only GFP (Ad.GFP) 
as the control. Expression of RGS16 protein correlated 
with GFP expression in cells treated with Ad.GFP.RGS16 
(Supplementary Figure 1). Fluorescent microscopy was 
used to determine viral transduction prior to experiment 
(Figures 5a, 6a, and 7a). EGF was used to stimulate cell 
migration because EGFR is overexpressed in pancreatic 
cancer and is linked with development, invasion, and 
decreased survival in pancreatic cancer [32-34]. RGS16 
significantly inhibited FBS- and EGF-induced migration 
of BxPC-3 cells and FBS-induced migration of AsPC-1 
cells, but had no effect on FBS and EGF induced migration 
of PANC-1 cells (Figures 5-7).
Interestingly, expression of RGS16 in BxPC-3 cells 
incubated in media supplemented with EGF caused an 
increase in wound width compared to control 16 hours 
after the start of the experiment. However, MTT assay 
revealed that there was no statistically significant change 
in cell viability of FBS or EGF treated BxPC-3, PANC-1 
or AsPC-1 following expression of RGS16 compared to 
control cells expressing GFP (Supplementary Figure 2).
Expression of RGS16 inhibited EGF induced 
invasion of BxPC-3 and AsPC-1 cells
RGS16 inhibited EGF induced migration of BxPC-
3 and AsPC-1 cells, we further investigated if RGS16 
can inhibit EGF induced invasion of these pancreatic 
cancer cells using matrigel invasion chambers. Media 
supplemented with EGF was used as the chemoattractant 
to induce migration and invasion of BxPC-3 and AsPC-1 
cells expressing GFP and or RGS16. Expression of RGS16 
significantly inhibited EGF induced invasion of the BxPC-
3 and AsPC-1 cells by 35.73% and 66% respectively, 
compared to control (Ad.GFP) (Figure 8).
DISCUSSION
Significance of investigating p53 and pRb cross-
talk
Historically, investigations of p53 and pRb regulated 
transcription have focused on identifying the individual 
downstream targets of p53 and pRb. However, cell fate 
is not determined solely by one signaling pathway but 
by many pathways that communicate through a network 
Figure 7: Expression of RGS16 inhibited migration of AsPC-1 cells. Wound healing assays were performed as described 
in Figure 2. A) Fluorescent microscopy was used to verify virus transductions: B) 100 X images were taken of migrating cells and C) 
percentages of wound healing were calculated at 24hrs following addition of FBS or EGF.
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of signaling molecules. Cross-communication between 
pathways allows the integration of the exogenous and 
endogenous signals in a cell to aid in the determination of 
cell fate. Previous studies have found that co-expression 
of p53 and pRb in cancer cells with compromised p53 
and pRb activity inhibited p53 mediated apoptosis and 
promoted cell cycle arrest suggesting p53 and pRb cross-
talk to regulate cellular fate [35, 36]. Furthermore, data 
from previous studies suggests p53 and pRb may also 
cooperate to inhibit cancer progression. Patients diagnosed 
with breast cancer and treated with adjuvant chemotherapy 
had a better prognosis to adjuvant chemotherapy if they 
had functional p53 and pRb [37].
To our knowledge this is the first study that 
examines altered gene expression when p53 and pRb 
are expressed together or separately with the purpose 
of finding genes co-regulated by both tumor suppressor 
genes. How p53 and pRb cross-communicate to 
regulate cellular functions or cooperate to inhibit cancer 
progression still remains largely unknown. The p53 and 
pRb pathways are commonly altered during tumorigenesis. 
Due to the dynamic properties of cell signaling, the study 
of genes dually regulated by p53 and pRb will provide a 
valuable insight into the collaborative cancer preventative 
properties of these two tumor suppressor proteins.
Transcriptional regulation may be one method 
used by p53 and pRb to coordinate cellular functions. 
For example, the cyclin kinase inhibitor p21 is a down-
stream target gene of p53 that inhibits phosphorylation 
and inactivation of pRb [25]. Transactivation of p21 
demonstrates a mechanism by which p53 can coordinate 
with pRb to initiate cell cycle arrest. However, this only 
begins our understanding of the complex regulation of 
cellular programs.
Change in RNA expression profiles of WI38 
cells expressing both p53 and pRb compared to 
expression of p53 and pRb alone, identification of 
cross-talk candidates, and validation by qRT-PCR
In this study, we identified genes that may be 
regulated by p53 and pRb and compiled two lists of p53 
and pRb cross-talk candidates by expressing p53 and/
or pRb in WI38 cells. Although p53 has transcriptional 
repression activity, our microarray analysis did not 
detect any down-regulated transcripts in the WI38 
cells expressing p53 [38, 39]. The deficit of p53 down- 
regulated transcripts in our microarray analysis compared 
to previous studies could be due to our method of p53 
activation, cell type, or p53 levels, which have previously 
been found to induce a distinct p53 response with a small 
set of overlapping genes [40, 41]. Our expression profiling 
analyses were conducted in normal lung fibroblasts cells 
instead of cancer epithelial cells. Absence of p53 down-
regulated genes in the p53 expressing WI38 cells could 
Figure 8: Expression of RGS16 inhibited invasion of BxPC-3 and AsPC-1 cells. Matrigel invasion chambers were used 
to measure cell migration and invasion of GFP and/or RGS16 expressing BxPC-3 (A & B) and AsPC-1 (C & D) cells using EGF as 
a chemoattractant. Migrated cells were stained with Crystal Violet and counted at 200x magnification (A &C). Percent invasion was 
calculated for each cell line (B & D) * p-value < 0.05. 
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also be attributed to the ability of p53 and pRb to alter 
each other’s transcriptional activation or repression 
functions in normal cells that contain intact pathways. 
Previous studies that discovered p53 down-regulated 
targets using expression profiling were done in cancer 
cells with mutated or null p53 and wild-type RB1 such as 
PC-3, HCT116, and H1299 cells [38, 42].
There were 319 upregulated transcripts when p53 
and pRb were expressed together compared to 427 and 295 
in the WI38 cells expressing pRb and p53 respectively. 
The change in upregulated genes suggests p53 and pRb 
can alter one another’s ability to regulate gene expression. 
Management of p53 and pRb processes may require 
p53 and pRb to regulate gene expression in an opposing 
manner. Expression of an embryonic development gene, 
Placenta- specific 1 (PLAC1), has recently been found 
to be down-regulated by p53 and up-regulated by pRb 
demonstrating how p53 and pRb can play contrasting roles 
to regulate cellular processes [43].
pRb is most associated with transcriptional 
repression of E2F target genes preventing transcription 
of genes needed for the continuation of the cell cycle 
[44-46]. However, binding of E2F by pRb is not needed 
to promote transcription, suppress tumor growth and 
induce cellular differentiation or senescence [47, 48]. 
In fact, pRb has been found to act as a co-activator for 
several transcription factors including Sp-1, RUNX-2, 
MyoD, and several nuclear receptors (including NR4A1) 
resulting in cellular differentiation [48, 49]. We found 
more transcripts that were up-regulated in WI38 cells 
expressing pRb than downregulated demonstrating its 
function as a transcription co-activator. There is still a 
lot not known about pRb regulation, therefore, this study 
could contribute to the identification of genes up-regulated 
by pRb and understanding of the function of pRb as a 
transcriptional co-activator.
Candidates for the p53 and pRb cross-talk pathway 
were chosen based on whether (1) the transcripts were 
differentially expressed in both WI38-p53 and WI38-
pRb-expressing cells (the common gene set), or (2) only 
in WI38 cells that simultaneously expressed p53 and pRb 
(interaction gene set). By focusing on the p53 and pRb 
common and unique genes, we were able to remove from 
our analysis genes regulated by p53 or pRb alone. Several 
of the p53 and pRb common gene set (RGS16, BTG-2, 
GDF15, VCAN, D4s234e/NSG1, AKR1B10 and AREG) 
and interaction gene set (F11R, TNFRSF10C, CERS6, 
HDM2, SESN1, RBM38 and PMAIP1/NOXA) cross-talk 
candidates have been previously found to be up-regulated 
by p53, and this data is in agreement with our microarray 
results [15, 41, 50-58]. Only a few of the downregulated 
p53 and pRb cross-talk candidates have previously been 
found by other studies to be downregulated by p53 
(MCM3, BUB1, and CDT1) or pRb individually (VRK1, 
MCM3, and CDT1) [38, 59-62]. Although several of our 
p53 and pRb cross-talk candidates have previously been 
found regulated by p53, regulation of these transcripts by 
pRb is not known.
Our expression profiling analysis was performed 
using a normal cell line in order to avoid any mutations 
that could be present up- or downstream of p53 and pRb 
that could hinder identification of downstream targets 
of both genes. Although we expressed p53 and pRb 
using adenoviruses in normal cells, the fold change of 
p53 and hypophosphorylated pRb proteins compared to 
CMV control were equivalent to or less than fold change 
values in WI38 cells incubated in serum free media 
to induce quiescence (fold change p53 after 24 hours 
in serum free media = 5.5) or MCF7 cells undergoing 
confluence induced cell growth arrest (fold change 
hypophosphorylated pRb/total pRb = 6.00) [30, 31]. 
This data suggests the concentration of virus used did 
not exceed endogenous protein expression of p53 and the 
active hypophosphorylated form of pRb. However, the use 
of a normal cell line with wild-type p53 and RB1 could 
make it difficult to identify cross-talk molecules due to 
possible interactions between endogenous and exogenous 
p53 and pRb. To investigate if exogenous and endogenous 
p53 and pRb interactions could influence expression 
profiles expression of RGS16, BCL2L11, BTG-2, IL-6, 
and STAT4, were measured using qRT-PCR in the p53 
null and pRb mutated osteosarcoma cell line SAOS-2. 
Expression of all transcripts in the p53 and pRb expressing 
SAOS-2 cells were found increased with differences 
in magnitude of expression as they did in our WI38 
microarray data and qRT-PCR results. Interestingly, in 
the microarray data, STAT4 was found to be differentially 
expressed in WI38 cells expressing p53 and pRb but 
not in cells expressing both genes. However qRT-PCR 
analysis found a statistically significant increase in STAT4 
expression in WI38 and SAOS-2 cells expressing p53 and 
pRb. The statistical analyses of expression profiling data 
or the sensitivity of microarray signal detection could 
account for the failure to observe differential expression 
of STAT4 in WI38 cells expressing p53 and pRb.
RGS16 significance and signaling in cancer
RGS16 was of interest to our study for two reasons: 
1) RGS16 regulates GPCRs, which are common targets 
for deregulation in cancer and 2) RGS16 has been linked 
to regulating the MAPK/RAS, PI3K/AKT, RhoA, and 
SDF-1/CxCR4 oncogene pathways [15, 17-19, 63]. 
Investigations have found that oncogene pathways 
can feed into one another and bypass or overcome the 
inhibitory effects of monoclonal antibodies or other 
targeted inhibitors. For example, in melanoma, increased 
production of VEGF or increased expression or activation 
of the platelet-derived growth factor receptor β or insulin 
like growth factor 1 receptor is associated with resistance 
to BRAF inhibitors demonstrating mechanisms cancer 
cells use to overcome single target modalities [64]. 
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Therefore investigation of RGS16, a protein known 
to modulate several oncogene pathways will aid in 
understanding mechanisms by which cells alter multiple 
signaling pathways to prevent carcinogenesis that could 
be used for future drug development.
We chose to study the function of RGS16 in 
pancreatic cancer because only 5.7% (1 out of 17) of 
pancreatic tumors with lymph-node metastases had 
expression of RGS16 compared to 70.6% (12 out of 17) of 
pancreatic tumors with non-metastasized pancreatic cancer 
[26]. Furthermore, decreased expression of RGS16 was 
associated with poor pancreatic cancer patient survival 
indicating the potential of RGS16 as a pancreatic cancer 
prognostic marker [26].
Few reports have been published that describe the 
impact of RGS16 on cancer cell signaling and progression. 
Although increased expression of RGS16 has been found 
in pediatric high hyperdiploid acute lymphoblastic 
leukemia (ALL) and colon cancer, functional analysis of 
RGS16 has not been performed to identify any oncogenic 
function in these cancers [26, 65, 66]. Functional and 
expression analysis of RGS16 has been performed in 
breast cancers. The RGS16 promoter is located at a site 
that is vulnerable to allelic imbalances in a subset of breast 
cancers that can result in promoter methylation of RGS16 
in 10% of these cancers [25]. Liang et al. (2009) found 
that RGS16 overexpression in breast cancer cell lines 
decreased EGF induced proliferation and AKT activation 
by binding to the p85-alpha subunit of PI3K preventing 
the phosphorylation of AKT [19]. RGS16 has also been 
associated in the anti- proliferative effect of retinoic acid 
in neuroblastoma cells and the cytotoxic effect of histone 
deacetylase inhibitor Vorinostat in triple negative breast 
cancers [67, 68]. The current data suggests RGS16 plays a 
role in cancer signaling, however, more research is needed 
to delineate the function of RGS16 in cancer cells.
RGS16 and cell migration
RGS16 has been linked with inhibition of cell 
migration in a canonical (through regulation of GPCR 
signaling) and non-canonical pathways in normal cells. 
RGS16 inhibits megakaryocytes and T lymphocyte 
migration by regulating the activation of the GPCR 
CxCR4 and decreases T helper type 2 and 17 cell 
trafficking through regulation of CCR4 and CCR10 
chemokine pathways representing the canonical form of 
RGS signaling [17, 69, 70]. The activation of RhoA, a 
small GTPase involved in reorganizing actin cytoskeleton 
and a mediator of EGF induced invasion of pancreatic 
cancer cell lines is inhibited in MCF-7 cells by the 
relocation of Gα13 to the plasma membrane by RGS16 
preventing Gα13 mediated activation of RhoA [18, 
71]. The regulation of RhoA activation by RGS16 is an 
example of a non-canonical mechanism used to regulate 
signaling. These studies show mechanisms by which 
RGS16 can regulate cell migration. To date, this is the first 
report demonstrating RGS16 induced inhibition of cancer 
cell invasion.
The findings from our study suggest RGS16 
is regulated by p53 and pRb and functions to inhibit 
pancreatic cancer cell migration and invasion; however 
this effect was cell line dependent. PANC-1 cell migration 
induced by FBS or EGF was not inhibited by RGS16, this 
could be due to different mutations in PANC-1 compared 
to the other cell lines that prevent RGS16 inhibition 
of FBS or EGF induced cell migration. Although not 
commonly associated with p53 and pRb signaling, 
regulation of cellular migration and invasion by both 
tumor suppressors has become evident over the course 
of the past several years. p53 has been found to regulate 
cell polarization and migration of cells predominately by 
inhibiting Rho signaling [72]. p53 also inhibits cancer 
cell invasion by inhibiting activity or expression of 
matrix metalloproteinases (MMPs) [73-76]. pRb’s role in 
cell migration has recently come to light. pRb has been 
implicated as an important factor in regulating neuronal 
cell migration and was recently found to inhibit CD44 
induced collective cell migration of breast cancer cells [77, 
78]. pRb is linked to regulating invasion through its ability 
to bind and inhibit E2F induced transcriptional activation 
of the MMPs 9, 14, and 15 [79]. Knock-down of E2F1 and 
E2F3 inhibited migration and invasion of non-small cell 
lung cancer cells [79]. RGS16 may be another mechanism 
employed to regulate cell migration and invasion by p53 
and pRb.
Future studies and conclusions
This is the first report of regulation of RGS16 by 
pRb and RGS16-mediated inhibition of EGF- induced 
migration and invasion in normal and cancer cells. This 
study focused on examining migration and invasion 
mediated by the EGF/EGFR pathway. However, a single 
RGS protein can interact and regulate signaling of 
multiple pathways ([16, 80]). Future studies are needed 
to determine if RGS16 can inhibit cell migration and 
invasion through other pathways such as the SDF-1/
CxCR4 pathway which is deregulated in pancreatic cancer 
([21]).
By utilizing microarray expression profiling, we 
have 1) identified p53 and pRb regulated candidates genes 
involved in coordinating cancer suppression processes and 
determining cell fate, 2) and identified a possible role for 
the cross-talk candidate RGS16 in inhibiting pancreatic 
cancer cell migration and invasion. Our study suggests that 
the loss of RGS16 promotes pancreatic cancer metastasis 
by removing the inhibitory function of RGS16 on cell 
migration and invasion. Our study further supports the use 
of RGS16 as a prognostic marker for predicting pancreatic 
cancer metastasis previously described by Kim et al. that 
can be used to assess eligibility of patient for surgery 
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[26]. By investigating the p53 and pRb cross-talk and the 
role of RGS16 in pancreatic cancer cell migration, we 
have uncovered a novel regulator of metastatic processes 
that could be a future target in developing treatments to 
prevent the spread of pancreatic cancer.
MATERIALS AND METHODS
Cell culture and virus transductions
The human lung fibroblast WI38 cell line, 
osteosarcoma cell line SAOS-2 (p53 null and truncated 
RB1), and the pancreatic cancer cell lines, BxPC-3, 
AsPC-1, MIA PaCa-2, and PANC-1 were purchased 
from the American Type Culture Collection (Manassas, 
VA, USA). WI38 cells were grown in Hyclone MEM/
EBSS (ThermoFisher Scientific, Waltham, MA) media 
supplemented with 10% research grade fetal bovine 
serum (FBS) (PAA Laboratories, Dartmouth, MA) and 
1% Penicillin Streptomycin (Corning, Corning, NY) and 
SAOS-2, MIA PaCa-2, and PANC-1 cells were grown in 
Hyclone High Glucose DMEM (ThermoFisher Scientific, 
Waltham, MA) supplemented with 10% FBS and 1% 
Penicillin Streptomycin. BxPC-3 and AsPC-1 were 
cultured in RPMI supplemented with 10% or 15% FBS 
(respectively) and 1% Penicillin Streptomycin. Cells were 
cultured at 37°C in a humidified 5% CO2 incubator.
Ad.CMV (adenovirus with CMV promoter) and 
Ad.CMV.p53 (Adenovirus containing wild- type p53 
gene under control of CMV promoter) viral vectors were 
generated using the AdEasy system (Carlsbad, CA). The 
Ad.CMV.pRb (Adenovirus containing RB1 gene cDNA 
under control of CMV promoter) vector was provided 
by Dr. Juan Fueyo (M.D. Anderson Cancer Center, The 
University of Texas). The Ad.GFP and Ad.GFP.RGS16 
viruses were purchased from Vector Biolabs (Philadelphia, 
PA). Viruses were amplified and titered as previously 
described [81-83].
Microarray expression profiling
For expression profiling, WI38 cells were transduced 
with each of the following vectors or vector combination: 
(1) adenovirus vector with no insert (Adenoviral CMV-
vector ctrl), (2) Ad.CMV.p53, (3) Ad.CMV.pRb, and (4) 
both Ad.CMV.p53 and Ad.CMV.pRb. Vectors were added 
at a multiplicity of infection (MOI) of 50 to 80% confluent 
WI38 cells in MEM/EBSS supplemented with 2% heat-
inactivated FBS. Culture media were replaced with 10% 
FBS and 1% Penicillin/Streptomycin supplemented 
MEM/EBSS medium 16 hours after vector addition; cells 
were collected after 48 hours. Four biological replicates 
were performed for each of the four expression studies. 
Immunoblots were used to verify increased expression of 
p53 and/or pRb in the WI38 samples prior to microarray 
analysis.
Total RNA was isolated from transduced WI38 
cells using TRIzol reagent (Invitrogen, Carlsbad, CA) 
according the manufacturer’s protocol. Using a universal 
reference design, two RNAs (transduced WI38 cells + 
Agilent (Santa Clara, CA) human universal reference 
RNA) were hybridized to Agilent 44K whole human 
genome expression arrays. Total RNAs were labeled with 
either cyanine (Cy)-3-CTP and Cy5-CTP (Perkin Elmer, 
Waltham, MA) using Agilent QuickAmp cRNA labeling 
kits. Following purification, Cy3- and Cy5-labeled cRNAs 
were combined and hybridized for 17 hours at 65ºC in an 
Agilent hybridization oven. Microarrays were then washed 
and scanned using Agilent DNA Microarray Scanner.
Statistical Analysis of Expression Profiling Data
Lowess-normalized feature intensities were 
extracted from the scanned image using Feature Extraction 
(Agilent). These data were exported as tab-delimited files 
(one file per sample) to Microsoft Excel for filtering. For 
each feature, data were removed if both channels reported 
values not well-above background according to default 
Feature Extraction Criteria. For each comparison, log 
base-2 ratios of each sample to universal reference RNA 
were collated into a single table. Features for which fewer 
than 50% of all samples had a present value were removed 
from further analysis.
The resulting tables were imported into Multiple 
Experiment Viewer (MEV) v4.3. Log base 2 ratios 
were compared between each of three sample sets (p53 
expressed samples. RB1 expressed samples and p53 and 
RB1 coexpressed samples) and the adenovirus vector 
control samples by Significance Analysis of Microarrays 
[84]. We used a conservative threshold whereby only 
genes for which MEV reported a false discovery rate of 
0% were considered significantly differentially expressed.
Data extracted using Feature Extraction was 
uploaded to the NCBI’s Gene Expression Omnibus 
(GEO) public database and is available via access number 
GSE59660.
Real-time PCR analysis
Total RNA was isolated from cells using TRIzol 
reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol. Total RNA was reverse 
transcribed into cDNA using the High Capacity cDNA 
Reverse Transcription kit from Applied Biosystems 
(Foster City, CA) according to the manufacturer’s 
protocol. Real-Time PCR was performed using the 
Applied Biosystems TaqMan Gene Expression Assays 
in the ABI 7000 detection system. TaqMan probes 
were purchased from Applied Biosystems (Foster City, 
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CA) IL-6 (HS00197982_m1), BCL2L11 (BCL2L11) 
(HS00197982_m1), RGS16 (HS00892674_m1), BTG2 
(HS00198887), STAT4 (HS00231372_ml) and GAPDH 
(HS02758991). Human pancreatic total RNA used 
for comparing the expression of RGS16 mRNA was 
purchased from Agilent Technologies (Cedar Creek, TX). 
The relative fold change for each marker was calculated 
using the 2-ΔΔCT analysis according to Livak et.al and 
statistical significance was determined using a one way 
ANOVA with a Dunnett’s or Tukey (pancreatic cancer 
cell lines) post-hoc test, using Prism V6.0c (GraphPad 
Software, Inc., La Jolla, CA) [85].
Western blot analysis
WI38 or Saos-2 cells were lysed in whole cell lysis 
buffer containing 50mM TRIS (pH7.4), 5mM EDTA 
250mM NACL, 50mM NaF, 0.1mM Na3VO4, 0.1% Triton 
X-100 and protease inhibitors (Pierce Protease inhibitor 
Tablets 88661; Thermo Scientific, Rockford, IL). Protein 
extracts (50ug) were loaded onto 8% polyacrylamide 
gels and proteins were separated using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Blots were blocked 1 hour in 5% dry non-fat milk 
diluted in Tris-buffered saline solution containing 0.1% 
Tween-20 (TBS-T). Membranes were probed overnight at 
4°C with mouse anti-p53 (SC-DO1, 1: 1000) or mouse 
anti-pRb (SC-IF8, 1:500) antibodies from Santa Cruz 
Biotechnology (Dallas, TX). Following primary antibody 
incubation the membranes were washed and probed 
with Horseradish peroxidase (HRP)-conjugated goat 
anti-mouse (1:5000) secondary antibodies (Rockland, 
Gilbertsville, PA) for 1 hour at room-temperature. 
Primary and Secondary antibodies were diluted in TBS-T. 
Blots were washed 5 minutes in TBS-T three times and 
Amersham ECL prime western blotting detection reagent 
was added in order visualize the protein bands (RPN2232, 
GE Life Sciences, Pittsburgh, PA). Western blot images 
were captured using FOTODYNE FOTO/Analyst FX 
(Hartland, WI) imaging camera. Membranes were 
normalized using mouse anti-actin (1:1000). Densitometry 
was performed using TotalLab Quant software (TotalLab 
Ltd, UK).
Wound healing Assay
Pancreatic cancer cells (BxPC-3, AsPC-1 and 
PANC-1) were placed in a 6 well plate at approximately 
70% confluency. The following day, 50 Multiplicity of 
Infection (MOIs) of Ad.GFP (control) or Ad.GFP.RGS16 
were added to the cells in media containing 2% heat-
inactivated FBS for 24 hours. The media was changed to 
complete media (10% FBS for BxPC-3 and PANC-1 or 
15% for AsPC-1) for 24hrs. 48 hours after the addition 
of the virus the media was changed from complete media 
to media supplemented with 0.5% FBS and 1% P/S for 
24hours. Three wounds or scratches were made per well 
using a p200 pipette tip in PBS. The cells were washed 
three times with PBS and incubated for 16-24 hours in 
complete media or media supplemented with 100ng/ml of 
EGF. FBS or EGF was added to induce cell migration at 
a concentration previously described in [86-88]. Wound 
widths were measured and images taken at 0, 16, or 24 hrs 
after addition of media supplemented with FBS or EGF at 
100x magnification using an Olympus DP71 microscope 
(Center Valley, PA). Efficacy of virus transduction was 
confirmed using fluorescent microscopy to examine GFP 
expression prior to the start of the experiment. Percent 
wound healing was determined using the following 
equation; % wound healing = ([initial scratch width – final 
scratch width]/ initial scratch width)*100. Three replicates 
were performed for each cell line.
Invasion Assay
BD Bio Coat Matrigel Invasion chambers (Bedford, 
MA) containing membrane with 8um pores were used to 
assess the role of RGS16 to inhibit pancreatic cancer cell 
migration and invasion. BxPC-3 cells were plated into 
6-well dish, 24 hours later 50 MOIs of Ad.GFP or Ad.GFP.
RGS16 virus were added to the cells followed by 24 
hour incubation in complete media and 24 hours in low-
serum media as described in the wound healing section. 
Chambers were re-hydrated in RPMI containing 1% P/S 
and 0.1 % BSA for 2 hours at 37°C. BxPC-3 and AsPC-1 
cells were collected and 25 x 104 cells were added to the 
top of the chambers in RPMI supplemented with 1% P/S 
and 0.1%BSA. RPMI supplemented with 100ng/ml EGF, 
1% P/S, 0.1% BSA was added to lower portion and the 
chambers were incubated for 18 (AsPC-1) or 20 (BxPC-3) 
hours at 37֯C. The non-migrating cells were removed using 
a cotton swab and the invaded cells were fixed using 100% 
methanol (MeOH) for 5 minutes and stained using 0.5% 
crystal violet plus 20% MeOH (10-15 mins). Invaded cells 
were counted using 200x magnification with 12 different 
views. Percentage of invasion compared to GFP control 
was calculated for each cell line [(# of invaded cellstreated 
/ # of invaded cellcontrol) *100]. Three replicates were 
performed for each cell line.
Statistical Analysis
Statistical significance for the wound healing and 
invasion assays was calculated using Student’s t-test using 
Prism V6.0c (GraphPad Software, Inc., La Jolla, CA). 
Statistical Analysis tests used for expression profiling and 
qRT-PCR analyses are listed in their respective sections.
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